AbbVie’s ABBV-932 Bipolar Depression Trial Reaches Completion: What Investors Should Watch Next

Abbvie (ABBV) announced an update on their ongoing clinical study.

Study Overview: AbbVie is running a Phase 2 trial called “Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects With Depressive Episodes Associated With Bipolar I or II Disorder.” The goal is to see how well oral ABBV-932 works and how safe it is for adults with bipolar I or II depression, a large and underserved mental health market where current options are limited and often poorly tolerated.

Intervention/Treatment: The study tests ABBV-932, an oral capsule taken once a day, against a matching placebo. ABBV-932 is an experimental drug designed to ease depressive symptoms in bipolar I and II disorder, with three different fixed doses being compared to a placebo control.

Study Design: The trial is interventional and randomized, meaning participants are randomly placed into one of four groups. It uses a parallel-group setup with three ABBV-932 dose arms and one placebo arm. The study is double-blind with masking across patients, doctors, and assessors, so no one knows who receives the active drug or placebo. The primary aim is treatment-focused, looking at both symptom improvement and side effects over a six-week period plus a follow-up.

Study Timeline: AbbVie first submitted the study in September 2024, marking the formal start of the program for investors to track. The trial is now listed as completed, signaling that patient treatment and primary data collection have finished. An estimated completion date is passed, meaning the company should now be analyzing results internally. The last update was filed on January 9, 2026, confirming that the record is current and suggesting AbbVie is actively curating the dataset ahead of a possible data release.

Market Implications: For AbbVie (ABBV), this bipolar depression program adds optionality beyond its core immunology and oncology franchises. A positive Phase 2 readout could support a larger, value-creating Phase 3 program and strengthen AbbVie’s presence in central nervous system disorders, an area with high unmet need and premium pricing potential. Even before full data, confirmation of trial completion and recent updates may support sentiment by showing clinical execution is on track. Investors will watch for efficacy strength, safety profile, and dose response, all key for assessing commercial odds. In the wider space, any promising signal from ABBV-932 would put AbbVie in more direct competition with incumbents in mood disorders and could re-rate expectations for peers pursuing next-generation psychiatric drugs. Until top-line results are disclosed, the update is more about de-risking timelines than changing near-term earnings forecasts.

The ABBV-932 bipolar depression study is now completed and recently updated, with more details available on the ClinicalTrials.gov portal.

To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.